The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level. The conditions and diseases that are characterized with an increased PAI-1 level, are regrouped within two categories: the diseases associated with an impaired vascular or tissue remodeling capacity, and the metabolic and hormonal disorders associated with an increased PAI-1 level.
